Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.63
+1.44 (6.49%)
At close: Dec 5, 2025, 4:00 PM EST
23.23
-0.40 (-1.69%)
After-hours: Dec 5, 2025, 7:59 PM EST
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Apellis Pharmaceuticals stock have an average target of 33.11, with a low estimate of 18 and a high estimate of 52. The average target predicts an increase of 40.12% from the current stock price of 23.63.
Analyst Consensus: Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Hold | 9 | 10 | 9 | 8 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 20 | 20 | 21 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $36 | Buy | Maintains | $40 → $36 | +52.35% | Nov 5, 2025 |
| Mizuho | Mizuho | Hold Maintains $24 → $19 | Hold | Maintains | $24 → $19 | -19.59% | Nov 3, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $52 → $45 | Strong Buy | Maintains | $52 → $45 | +90.44% | Oct 31, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $50 → $45 | Strong Buy | Maintains | $50 → $45 | +90.44% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
1.01B
from 781.37M
Increased by 29.00%
Revenue Next Year
884.42M
from 1.01B
Decreased by -12.26%
EPS This Year
0.27
from -1.60
EPS Next Year
-1.12
from 0.27
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.0B | ||||
| Avg | 1.0B | 884.4M | ||||
| Low | 684.3M | 771.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 41.2% | -0.5% | ||||
| Avg | 29.0% | -12.3% | ||||
| Low | -12.4% | -23.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.50 | 0.44 | ||||
| Avg | 0.27 | -1.12 | ||||
| Low | 0.13 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 67.1% | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.